Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models. RESULTS: In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02-1.42), P = 0.03; multivariate HR for OS: 1.41 (1.17-1.70), P < 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59-3.02), P < 0.001] and OS [multivariate HR: 2.99 (2.10-4.25), P < 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (n = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25-4.1), P = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [n = 71, multivariate HR 1.46 (0.96-2.22), P = 0.10]. More frequent KRAS exon 2 variants like G12D [n = 152, multivariate HR 1.17 (0.86-1.6), P = 0.81] and G12V [n = 92, multivariate HR 1.27 (0.87-1.86), P = 0.57] did not have significant impact on OS. CONCLUSION: Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [9]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the KRAS p.G12C mutation is associated with poorer prognosis in terms of progression-free survival (PFS) and overall survival (OS) compared to other KRAS mutations as well as KRAS wild-type tumors.4-7”
From Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A pooled analysis by the Arbeitsgemeinschaft Internistische Onkologie [AIO] study group revealed that KRAS G12C mutation was significantly associated with lower OS compared with tumors with no KRAS mutations [16]”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with other KRASm, including KRAS G12A/D/S/V and KRAS G13D, had OS times ranging from 17.6 to 25.2 months.51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
In the citing paper
“A post hoc analysis of pooled clinical data from 1239 patients from 5 randomized trials, in which patients with mCRC were treated with chemotherapy with or without bevacizumab as first-line treatment (67%), reported that patients harboring KRAS G12C had the shortest median OS (16.8 [95% CI: 15.6, 18.0] months).51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 3×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · cited 1×
“patients andmethods studies This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [14, 15], FIRE-3 (only bevacizumab-arm) [2, 16, 17], AIO KRK 0604 [18], AIO KRK 0207 [19] and RO91 [20].”
MethodSelf-citationCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 3×
“well with recent reports of first-line treatment in mCRC [5, 24].”
BackgroundResultVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationBokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Research works printed but not linked: 1
- 19. Stintzing S, Jung A, Rossius L, Modest DP et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. In ESMO/ECCO, 2013; Abstract E17-7073.
Cited by
Items 201–300 of 351
Österlund, E., Ristimaki, A. P., Nunes, L., Kytölä, S. I., Aho, S., Heervä, E., Uutela, A., Lehtomäki, K., Stedt, H., Halonen, P., et al. (2025) · BJC Reports · doi:10.1038/s44276-025-00188-5 · Cited by 5
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 7
New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients
Ruffinelli, J. C., Vivas, C. S., Pamplona, R. S., & Moreno, V. R. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1826305 · Cited by 4
Allart, M., Leroy, F., Kim, S. C. H., Sefrioui, D., Nayeri, M., Zaanan, A., Rousseau, B., Abdelghani, M. B., de la Fouchardière, C., Cacheux, W., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.06.031 · Cited by 6
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Xiao, A., & Fakih, M. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.004 · Cited by 7
Abdelgadir, O., Kuo, Y., Khan, M. F., Okorodudu, A. O., Cheng, Y., & Dong, J. (2025) · Diagnostics · doi:10.3390/diagnostics15050590 · Cited by 7
Alawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., Moore, J., Maddern, G., Roder, D., Smith, A., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00856-9 · Cited by 5
Goud, K. I., Matam, K., Madasu, A. M., & Khan, I. A. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03119-6 · Cited by 6
Wiederkehr, J. C., Wiederkehr, B. A., & Wiederkehr, H. D. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80558 · Cited by 5
Xu, C., Ren, J., Liu, C., Gai, Y., Cheng, X., Wang, Y., & Wang, G. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001697 · Cited by 4
Oncogenic mutations of clinical significance in colorectal cancer
Lea, V., Lim, S. H.-S., & Lee, C. S. (2025) · Pathology · doi:10.1016/j.pathol.2025.05.001 · Cited by 4
Italiano, A., Gautier, O., Dupont, J., Assi, T., Dawi, L., Lawrance, L., Bône, A., Jardali, G., Choucair, A., Ammari, S., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115609 · Cited by 12
The impact of RAS mutation on the treatment strategy of colorectal cancer
Pirvu, E. E., Severin, E. M., Niţă, I., & Toma, Ş. A. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2408 · Cited by 5
Wu, X. L., Liu, W., Wang, Y., Wang, K., & Xing, B. (2024) · Cancer Medicine · doi:10.1002/cam4.70168 · Cited by 4
Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations
Parikh, P. M., Bahl, A., Sharma, G., Pramanik, R., Wadhwa, J., Bajpai, P., Jandyal, S., Dubey, A. P., Sarin, A., Dadhich, S. C., et al. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0044-1791689 · Cited by 4
Omrčen, T., Katić, A., Tomić, S., Eterović, D., & Vrdoljak, E. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000892 · Cited by 4
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
Beypınar, İ., Demir, H., Sakin, A., Taşköylü, B. Y., Şakalar, T., Ergün, Y., Korkmaz, M., Ateş, Ö., Eren, T., Turhal, S., et al. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00514-9 · Cited by 4
Adenis, A., Mazard, T., Fraisse, J., Chalbos, P., Pastor, B., Evesque, L., Ghiringhelli, F., Mollévi, C., Delaine, S. C., & Ychou, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08312-7 · Cited by 5
Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer
Baek, J. H., Kim, J., Baek, D. W., Chang, E., Kim, H. J., Park, S. Y., Park, J. S., Choi, G., Kang, B. W., & Kim, J. G. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10079 · Cited by 4
Toledo, D. C., Jiménez‐Fonseca, P., López, C., Montés, A. F., Muñoz, A. M. L., Rivera, F. V., Alonso, V., Alcaide, J., Salvà, F., Rúa, M. C., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02563-w · Cited by 5
Tsuda, Y., Okajima, K., Ishibashi, Y., Zhang, L., Hirai, T., Kage, H., Shinozaki‐Ushiku, A., Oda, K., Tanaka, S., & Kobayashi, H. (2024) · Medicine International · doi:10.3892/mi.2024.141 · Cited by 5
Kim, J., Kim, H., Hong, J. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., & Kim, S. T. (2020) · Journal of Cancer · doi:10.7150/jca.49176 · Cited by 4
TAS-102 and the quest for predictive biomarkers
Velden, D. L. V. D., Opdam, F. L., & Opdam, F. L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000263 · Cited by 5
Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G. A., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D. P. S., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100042 · Cited by 5
Hitchen, N., Wong, H., Wong, R., Shapiro, J., Burge, M., Nott, L., Lee, B. R., Lim, S. H.-S., Wong, S. F., Caird, S., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100178 · Cited by 4
Wang, Z., Qin, B., Ye, C.-Y., Wang, M., Yuan, L., Yao, H., Jiao, X., Liu, K., Zhou, W., Qin, W., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02383-9 · Cited by 8
Kastinen, M., Härkönen, J., Sirniö, P., Elomaa, H., Karjalainen, H., Äijälä, V. K., Tapiainen, V. V., Sirkiä, O., Pohjanen, V., Ahtiainen, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2026 · Cited by 4
Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., et al. (2026) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(25)00267-5 · Cited by 3
Liu, X., Ou, K., Ma, X., Yang, W., Cao, B., Lu, J., Zhang, L., Gao, L., Wang, Q., Zhang, W., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106056 · Cited by 3
Wang, H., Yu, H., Yang, Y., Fu, M., Geng, L., Wang, J., Yue, Y., Zhang, Q., & Wu, N. (2026) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2026.125185 · Cited by 6
Petit, J. A., Carroll, G. M., Zhao, J., Pockney, P. G., & Scott, R. J. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010008 · Cited by 3
Yokoi, R., Mori, T., Hirosawa, K. M., Kondo, R., Taguchi, T., Matsuhashi, N., & Suzuki, K. G. N. (2025) · iScience · doi:10.1016/j.isci.2025.113374 · Cited by 4
Prognostic Factors for Survival in Transverse Colon Cancers
Küçükarda, A., Gökyer, A., Sayın, S., Gökmen, İ., Özcan, E., Köstek, O., Hacıoğlu, M. B., Uzunoğlu, S., Çiçin, İ., & Erdoğan, B. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00675-1 · Cited by 3
Li, M., Keshavarz-Rahaghi, F., Ladua, G. K., Swanson, L., Speers, C., Renouf, D. J., Lim, H. J., Davies, J. M., Gill, S., Stuart, H., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221097940 · Cited by 5
Radioembolisation of liver metastases
Boshell, D., & Bester, L. (2023) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13549 · Cited by 4
Moretto, R., Rossini, D., Murgioni, S., Ciracì, P., Nasca, V., Germani, M. M., Calegari, M. A., Vetere, G., Intini, R., Taravella, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00329 · Cited by 5
Chen, K., Qu, Y., Han, Y. R., Li, Y., Gao, H., & Zheng, D. (2025) · Journal of Medical Internet Research · doi:10.2196/73528 · Cited by 5
Tumor Genetics Are Thrombogenic
Mahé, I., Scotté, F., & Elalamy, I. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.03.002 · Cited by 3
Fedyanin, M. Y., Максимовна, П. Е., Elsnukaeva, H., Tryakin, A. A., Покатаев, И. А., Bulanov, A., & Tjulandin, S. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-20-125-132 · Cited by 3
Ren, C., Qin, Y., Cao, D., Ren, X., Zhao, H., Han, J., & Du, G. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70353 · Cited by 2
Prognostic Impact of RAS and TP53 Mutation Profiles in Metastatic Colorectal Cancer
Duygulu, M. E., Karaman, E., Karakullukçu, S., & Munğan, S. (2026) · Medicina · doi:10.3390/medicina62010136 · Cited by 2
Yin, W., Wu, X., Li, T., Yuan, Z., Qin, L., & Li, Q. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04301-z · Cited by 2
Fan, J., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., 张苏展, et al. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00062-6 · Cited by 3
Marschner, N. W., Seufferlein, T., Potthoff, K., Zahn, M., Uhlig, J., Dörfel, S., Karcher, A., Sauer, A., Maintz, C., Fruehauf, S., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100040 · Cited by 5
Ou, K., Liu, X., Ma, X., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1461237 · Cited by 2
Ekmekçiu, I., Zucha, D. M., Christmann, J., Wisser, S., Heuer, V., Sargin, B., Hollerbach, S. H., Lamberti, C., Müller, L., Lugnier, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1434791 · Cited by 2
Self-citationLiang, Z., Huang, X., Mao, J., Xie, J., Li, X., & Li, Q. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03843-w · Cited by 2
Fedyanin, M. Y., Elsnukaeva, H., Демидова, И. А., Stroyakovskii, D., Shelygin, Y. A., Цуканов, А. С., Sergeev, Y. S., Пономаренко, А. А., Панина, М. В., Шубин, В. П., et al. (2022) · Malignant tumours · doi:10.18027/2224-5057-2021-11-3-5-14 · Cited by 2
Cancer Genomic and Epigenomic Variations in Sub-Saharan Africa
Adedeji, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-52554-9_2 · Cited by 2
Thomopoulou, K., Tzardi, M. N., Mavroudis, D., & Souglakos, I. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/4767019 · Cited by 2
Brain Metastasis in a Young Patient: Consider the Rectum
Shaikh, A. S., Pavurala, R. B., & Gou, E. (2021) · Cureus · doi:10.7759/cureus.20055 · Cited by 2
Conde-Moreno, A. J., del Alba, A. G., López‐Campos, F., López, C., Hernando, O., de Castro, J., Chicas-Sett, R., Arias, L. D. P., Montero-Luis, Á., Pérez, A. R., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-03019-y · Cited by 2
Higami, S., Mukai, M., Yokoyama, D., Uda, S., Abe, R., Mamuro, N., Kishima, K., Hasegawa, S., Tajima, T., Nomura, E., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-899 · Cited by 3
Prognostic value of gender and primary tumor location in metastatic colon cancer
Grassadonia, A., Carletti, E., Luca, A. D., Vici, P., Lisa, F. S. D., Filomeno, L., Cicero, G., Lellis, L. D., Veschi, S., Florio, R., et al. (2023) · Journal of Cancer · doi:10.7150/jca.85748 · Cited by 4
KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view
Schmitz, K., Schatz, C., & Knabl, L. (2024) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-024-00986-6 · Cited by 3
Treatments That Block Proteins Involved in Cell Communication
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch3 · Cited by 2
Initial Systemic Chemotherapy for Metastatic Colorectal Cancer
Yu, I. S., Advani, S., & Kopetz, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_31 · Cited by 1
Han, Z., Song, C., Li, D., Zhu, W., Sun, J., Yao, J., Gan, W., Wang, F., Yang, X., & Zhu, L. (2024) · Journal of Cancer · doi:10.7150/jca.94410 · Cited by 1
Onur, İ. D., Akdur, P. Ö., Sertesen, E., Çiledağ, N., & Yıldız, F. (2024) · Future Oncology · doi:10.1080/14796694.2024.2406221 · Cited by 1
Libby, D. M., Libby, L. J., Ma, X., Chua, J. M. W., Blow, T., Razavi, P., & Saxena, A. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.10.016 · Cited by 2
THE BIOLOGICAL CHARACTERISTIC OF THE ARCTIC CISCO IN THE WESTERN PART OF THE AREAL
Novoselov, A. P. (2024) · Practice Oriented Science: UAE – Russia – India · doi:10.34660/inf.2023.76.86.025 · Cited by 1
Feng, H., Zhao, L., Xu, Z., Xie, Q.-F., Deng, H., Jiang, Y., & Liu, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i5.102767 · Cited by 2
Penile Metastasis as the Presenting Symptom of Colorectal Carcinoma: A Rare Case Report
Patel, M., Kaldany, A., Tanko, F., Parrott, A. M., & Jang, T. L. (2025) · Case Reports in Urology · doi:10.1155/criu/8856762 · Cited by 1
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development
Chamseddine, S., Azmi, A. S., & Saif, M. W. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2611395 · Cited by 2
Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020
Siebenhüner, A. R. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.017 · Cited by 1
Epidemiology and risk factors for metastatic colorectal disease
Ward, E. P., & Clarke, C. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91706-3.00014-x · Cited by 1
Zurloh, M., Goetz, M., Herold, T., Treckmann, J. W., Markus, P. M., Schumacher, B. M., Albers, D., Rink, A., Rosery, V., Zaun, G., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05141-y · Cited by 1
Zhang, X., Ma, H., He, Y., He, W., Chen, N., Li, Y., Zhong, W., Wu, G. S., Zhou, X., Hua, H., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225035 · Cited by 2
Imai, T., Shoji, H., Hirano, H., Matsuguma, K., Awatsu, T., Hirose, T., Okita, N. T., Takashima, A., & Kato, K. (2024) · CNS Oncology · doi:10.1080/20450907.2024.2347824 · Cited by 2
Genetic Profiling and Survival Outcomes in Romanian Colorectal Cancer Patients
Vesa, A., Maghiar, O. A., Pop, O. L., Boros, M., Paşcalău, A. V., Molnar, O., & Maghiar, A. M. (2024) · Cureus · doi:10.7759/cureus.62390 · Cited by 1
Adenis, A., Ghiringhelli, F., Gauthier, L., Mazard, T., Evesque, L., Evrard, A., Chalbos, P., Moussion, A., Gourgou, S., & Ychou, M. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04682-4 · Cited by 1
Onkologische Therapiekonzepte bei systemischer Metastasierung des kolorektalen Karzinoms
Modest, D. P., & von Bergwelt‐Baildon, M. (2019) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-0895-6007 · Cited by 1
Self-citationBiomarkers in colon cancer and its clinical implications
Pavithran, K., & Srinivasalu, V. K. (2020) · Journal of Current Oncology · doi:10.4103/jco.jco_38_20 · Cited by 1
Cui, Y., Ou, Y., Luo, Y., Yu, J., Lin, Y., & Chen, S. (2021) · SAGE Open Medical Case Reports · doi:10.1177/2050313x211027737 · Cited by 1
Mizukami, T., Takahashi, M., Sunakawa, Y., Yuki, S., Kagawa, Y., Takashima, A., Kato, K., Hara, H., Denda, T., Yamamoto, Y., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00880-3 · Cited by 2
Zhang, Y., Guan, H., Liu, S., Li, H., Bian, Z., He, J., Zhao, Z., Qiu, S., Mo, T., Zhang, X., et al. (2025) · eLife · doi:10.7554/elife.103559 · Cited by 2
Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
Momenzadeh, H., Mirzai, M., Jowkar, Z., & Geramizadeh, B. (2018) · Middle East Journal of Digestive Diseases · doi:10.15171/mejdd.2017.85 · Cited by 4
Pathology of Rectal Cancer and Predictors of Response to Neoadjuvant Therapy
Berho, M. E., & Bejarano, P. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-98902-0_5
Colorectalis májmetastasisok komplex kezelése. Konszenzuskonferencia, Budapest, 2019. április 5.
Magyar Hepato-Pancreatico-Biliaris (HPB) Kutatócsoport, S. E., András, C., Bartek, P., Battyáni, I., Bezsilla, J., Bodoky, G., Bogner, B., Bursics, A., Csőszi, T., Damjanovich, L., et al. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31580 · Cited by 1
Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer
Pfeiffer, P., & Qvortrup, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-58846-5_21
Stahler, A., Modest, D. P., Stintzing, S., von Einem, J. C., Jelas, I., Heinrich, K., Holch, J. W., D’Haese, J. G., Angele, M. K., Pratschke, J., et al. (2021) · Forum · doi:10.1007/s12312-021-00923-2
Self-citationAdvances in Treatment Selection for Patients with Metastatic Colorectal Cancer
Schulte, B. C., & Benson, A. B. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.025
Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer
Barot, S. V., & Kamath, S. D. (2021) · Digestive Disease Interventions · doi:10.1055/s-0041-1727225
A roadmap for medical treatment of metastatic CRC
Martínez-Bernal, G., Martínez‐Pérez, J., & Valladares‐Ayerbes, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00016-8
Wiedmann, S. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-43
Cáncer de colon: desde Praxágoras hasta la cirugía robótica
Sergio, S., Bonilla, S., Cunha, G. V. D., & Pinato, F. (2022) · Cirugía del Uruguay/Cirugía del Uruguay · doi:10.31837/relatos/13
Molecular Diversity and Characteristics of KRAS Mutations in Colorectal Cancers
Kaler, A. K., Dharut, O., Umarji, S., Limaye, S., Kulkarni, B. N., Hastak, M., Athikari, N., Tiwarekar, Y., Rane, S., Nikam, A., et al. (2023) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1650
Loree, J. M., Wang, Y., Syed, M., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A. A., Raymond, V. M., et al. (2023) · doi:10.1158/1078-0432.c.6530433
Fountzilas, C. K., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., et al. (2023) · doi:10.1158/1078-0432.c.6530960
Loree, J. M., Wang, Y., Syed, M., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A. A., Raymond, V. M., et al. (2023) · doi:10.1158/1078-0432.c.6530433.v1
Fountzilas, C. K., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., et al. (2023) · doi:10.1158/1078-0432.c.6530960.v1
Stein, A. (2023) · best practice onkologie · doi:10.1007/s11654-023-00479-8
Максимовна, П. Е., & Fedyanin, M. Y. (2023) · Journal of Modern Oncology · doi:10.26442/18151434.2023.1.202012
Ou, K., Liu, X., Ma, X., & Yang, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2960624/v1
Clinicopathological correlations between colorectal cancer and genetic mutations
Vesa, A., Maghiar, O. A., Pop, O. L., Boros, M., Paşcalău, A. V., & Maghiar, A. M. (2023) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2023.3.7
Metadata
- Authors
- Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., & Reinacher-Schick, A.
- Affiliations
- German Cancer Research Center (DE)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Kliniken Maria Hilf (DE)
- LMU Klinikum (DE)
- University Hospital in Halle (DE)
- Ruhr University Bochum (DE)
- Corresponding author
- Modest, D.P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- 9
- Pages
- 1746-1753
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4999563
- OpenAlex
- W2465450966
- Semantic Scholar
- c6c03496c35c248a5905726558f97863fff59b9b
- Cited by
- 351
- References
- 31
- Citations by year
- 2026: 25 · 2025: 48 · 2024: 63 · 2023: 50 · 2022: 33 · 2021: 39 · 2020: 40 · 2019: 20 · 2018: 15 · 2017: 15 · 2016: 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1160 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, KRAS mutation, NRAS mutation, BRAF mutation, KRAS G12C, KRAS G13D, first-line therapy, progression-free survival, overall survival, predictive biomarkers, prognostic factors
- MeSH terms
- Female, Humans, Male, Membrane Proteins, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.